# A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

Clinical trial · CorrectSequence Therapeutics Co., Ltd

- Archive id: nct:NCT07489196
- Published: 2026-03-24
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07489196
- Source URL: https://clinicaltrials.gov/study/NCT07489196
- Provenance: clinicaltrials

## Abstract

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-Thalassemia Major

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: NOT_YET_RECRUITING
- phase: PHASE2
- study type: INTERVENTIONAL
- enrollment: 20
- sponsor: CorrectSequence Therapeutics Co., Ltd
- conditions: β-thalassemia Major
- interventions: GENETIC: CS-101 injection
- start date: 2026-04-05
- start date type: ESTIMATED
- primary completion date: 2028-01-31
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.